• Carbapenemase Gene Spread in Enterobacter cloacae During COV

  2026-08-04

  This study provides a detailed molecular epidemiology of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae across eight hospitals in Guangdong, China. It reveals high prevalence, multidrug resistance, and efficient horizontal transfer of these resistance genes, with implications for surveillance and antibiotic resistance research.

• Pam3CSK4 TFA: TLR1/2 Agonist for Innate Immunity Profiling

  2026-08-03

  Pam3CSK4 TFA is a synthetic TLR1/2 agonist that robustly activates innate immune responses and is widely applied in cytokine profiling and inflammatory research. As a highly pure, stable compound, it reproducibly induces IL-17A and other cytokines in both in vitro and in vivo assays. Its validated use in maternal-neonatal infection models underpins risk stratification and mechanistic studies.

• LncRNA FAISL Blocks Calpain 2-FAK Cleavage to Drive TNBC Pro

  2026-08-03

  This study uncovers how the lncRNA FAISL stabilizes FAK by inhibiting calpain 2-mediated proteolysis, thereby promoting the aggressiveness and metastasis of triple negative breast cancer (TNBC). These findings highlight a previously unrecognized regulatory mechanism of FAK and suggest new directions for targeted TNBC therapy.

• Mutational Landscape in Myeloma Cell Lines: Implications for

  2026-08-02

  This article analyzes a landmark study that mapped the exome-wide mutational landscape of 30 human multiple myeloma cell lines, identifying both established and novel genetic drivers associated with tumor progression and drug resistance. The findings provide a foundational reference for model selection, therapeutic strategy design, and the rational application of targeted agents in hematological malignancy research.

• Meropenem Trihydrate: Translational Leverage in Resistance R

  2026-08-01

  This article delivers a thought-leadership perspective on Meropenem trihydrate, a broad-spectrum carbapenem antibiotic, outlining its mechanistic foundation, strategic application in translational research, and the evolving landscape of resistance detection. Drawing on recent LC-MS/MS metabolomics findings and the APExBIO product portfolio, we present actionable guidance for researchers navigating the complexities of antibiotic resistance and translational infection models.

• Lovastatin in Translational Research: From Mechanism to Impa

  2026-07-31

  This thought-leadership article demystifies the multifaceted role of Lovastatin, a potent HMG-CoA reductase inhibitor, in advancing translational research. By weaving together mechanistic insights, experimental validation, and strategic guidance, it empowers researchers to unlock new dimensions in cellular metabolism, oncology, and inflammation. Drawing on recent literature and APExBIO product intelligence, the article establishes a new benchmark for leveraging Lovastatin across diverse scientific domains.

• Sodium Oxamate: Bridging Cancer Metabolism and Antiviral Res

  2026-07-31

  Explore how Sodium Oxamate, a competitive LDH-A inhibitor, is expanding applications beyond cancer metabolism research. This in-depth analysis uncovers its emerging role as a tool for probing glycolytic reprogramming in both oncology and viral pathogenesis.

• Protease Inhibitor Cocktail EDTA-Free: Enabling Precision in

  2026-07-30

  Discover how the Protease Inhibitor Cocktail EDTA-Free empowers sensitive protein studies, including phosphorylation analysis and cancer biomarker discovery. This article explores innovative applications, mechanistic insights, and practical protocols for preserving protein integrity.

• NHE3 Inactivation Drives PEDV-Induced Diarrhea in Neonatal P

  2026-07-30

  This study reveals that porcine epidemic diarrhea virus (PEDV) infection specifically diminishes the activity and membrane localization of the Na+/H+ exchanger NHE3 in intestinal cells, without affecting total protein levels. These mechanistic insights clarify how impaired sodium absorption precipitates life-threatening diarrhea in neonatal piglets and inform future research into targeted interventions.

• Quizartinib (AC220) in AML: Beyond FLT3 Inhibition to Next-G

  2026-07-29

  Explore the scientific depth of Quizartinib (AC220) for acute myeloid leukemia (AML) research, focusing on FLT3 autophosphorylation inhibition and advanced assay strategies. This article offers a unique, protocol-driven perspective that extends beyond standard FLT3 inhibition.

• Applied Workflows with JNJ-26854165 (Serdemetan) in Cancer R

  2026-07-29

  JNJ-26854165 (Serdemetan) is a small molecule HDM2 inhibitor that enables precise modulation of the p53 pathway, making it invaluable for anti-proliferative and apoptosis assays. This article translates the latest methodological advances into actionable protocols, troubleshooting strategies, and research design enhancements for maximizing the impact of Serdemetan in preclinical cancer models.

• EPZ5676 and DOT1L Inhibition: Shaping the Future of Leukemia

  2026-07-28

  This comprehensive thought-leadership article explores the strategic and mechanistic implications of EPZ5676, a highly selective DOT1L inhibitor, in translational research targeting MLL-rearranged leukemias. Integrating recent mechanistic insights, competitive benchmarking, and new evidence from histone modification studies, it delivers actionable guidance for researchers and positions EPZ5676 as a cornerstone of precision epigenetic workflows.

• Doxycycline Hyclate: Matrix Metalloproteinases Inhibitor in

  2026-07-28

  Doxycycline hyclate empowers researchers with robust inhibition of MMP-2 and MMP-9, enabling precise modeling of blood-brain barrier (BBB) integrity and neuroprotection. Its reproducible solubility, validated neurovascular applications, and protocol flexibility set it apart for translational studies on vascular and cognitive dysfunction.

• Optimizing Cell Assays: Practical Insights with α-Linolenic

  2026-07-27

  This article provides scenario-driven guidance for biomedical researchers using α-Linolenic Acid (SKU C3934) in cell viability and metabolic studies. It addresses real laboratory challenges, integrates evidence-based recommendations, and demonstrates how APExBIO’s product enhances assay reliability, reproducibility, and workflow efficiency.

• Sodium Oxamate: Unveiling a Metabolic Lever in Cancer Bioene

  2026-07-27

  Explore how Sodium Oxamate, a potent LDH-A inhibitor, enables advanced cancer metabolism research by disrupting lactylation-driven DNA repair and tumor resilience. This article offers novel insight into protocol optimization and translational opportunities, setting it apart from previous discussions of lactylation and radioresistance.

450 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page